← Leaderboards
Irida Kastrati
Loyola University Chicago
$2,252,222
Attributed
$2,252,222
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$2,252,222 · 1
By mechanism
R01$2,252,222 · 1
Top collaborators
No co-investigators on record.
Most similar at Loyola University Chicago
Same institution · by research overlap
- Amy H. Luke$4,706,646
- Elisa J Gordon$6,380,132
Others in their field
Other Rising Stars on “Acceleration”
- Angee Greer · Ppd Development Lp$82,531,927
- Julia Louise Moore Vogel · Scripps Research Institute, The$32,252,685
- Tim A Bertram · Wake Forest University School Of Medicine$30,163,580
- Nancy Jean Sullivan · Boston University Medical Campus$23,000,000
- Alanna Maguire · Mayo Clinic Rochester$16,353,346
- Michael Hogarth · University Of California, San Diego$15,375,743
Research focus
Acceleration3&AposAffinityAfrican AmericanAfrican American PopulationAffectAggressive Breast CancerAutomobile DrivingBindingBiological FactorsBiological MarkersBreast Cancer CellBreast Cancer ModelBreast Cancer PatientBreast Epithelial CellsBreast TumorigenesisCancer GenomeCandidate MarkerCaucasiansCell DeathCell Death InductionCell GrowthCell LineCells
Grant awards (3)
SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Health Disparity in Breast Cancer$1,356,803
R01 · FY2025 · CA · contact PI
SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Racial Disparity in Breast Cancer.$429,652
R01 · FY2024 · CA · contact PI
SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Racial Disparity in Breast Cancer.$465,767
R01 · FY2023 · CA · contact PI